Active ingredient: momelotinib

Brand name (sponsor): Omjjara (GlaxoSmithKline)

Presentation: 100 mg, 150 mg and 200 mg film-coated tablets

Route of administration: oral

Approved indication: treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus kinase (JAK) inhibitor–naive or have been treated with ruxolitinib